Immune-Related Adverse Events Diagnosis and Immunotherapy in Cancer
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 20594
Interests: clinical diagnosis; medical alternatives to hospitalization; systemic autoimmune diseases
Interests: cancer; oncological emergencies; supportive care; autoimmune diseases; infectious diseases; critical care; vasculitis; immunotherapy; immune-related adverse events
Special Issues, Collections and Topics in MDPI journals
Biological therapies are being used since more than one decade in autoimmune diseases, targeting with synthetic molecules (antibodies, soluble receptors, cytokines, or cytokine antagonists) diverse pathways related to the immune response. Its use, in continuous expansion, is promising and has allowed physicians to deepen their understanding of the immune system and its signaling pathways. This knowledge has been transferred to the oncologic field.
Immunotherapy as a cancer treatment has represented a paradigm shift for patients suffering from many types of malignancies. Some patients experience incredible responses to these treatments, even in advanced cancer diseases, but others suffer from unexpected autoimmune aggressions triggered by immunotherapy. These are called immune-related adverse events, being sometimes life-threatening and still representing challenging situations which require a multidisciplinary approach. It is clear that further clinical and translational research is warranted. Prevention of immune-related adverse events, its diagnosis and treatment, and even more importantly, implications in the treatment of patients with cancer when adverse events occur are still issues that need to be clarified and approached by the scientific community.
The main aim of this Special Issue, titled “Immune-Related Adverse Events Diagnosis and Immunotherapy in Cancer”, is to provide useful and interesting knowledge to physicians who take care of cancer patients regarding immunotherapy treatment and its yet poorly known adverse events. Content about adverse events diagnosis and management related to biological therapies in the scenario of autoimmune diseases treatment would also be considered appropriate.
Dr. Xavier Bosch
Dr. Javier Marco-Hernández
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune-related adverse events (irAE)
- cancer treatment
- immune checkpoint inhibitors
- immune oncology